Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

For the three months ended December 31st, 2017 vs December 31st, 2016, Ambev S.A reported revenue of $4,629.36MM vs $3,904.36MM (up 18.57%) and basic earnings per share -$0.00 vs $0.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ambev S.A reported revenue of $15,002.06MM vs $13,074.27MM (up 14.74%) and basic earnings per share $0.15 vs $0.23 (down 35.72%). Ambev S.A is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.05. The estimated EPS forecast for the next fiscal year is $0.31 and is expected to report on March 7th, 2019.

For the twelve months ended December 31st, 2017 vs December 31st, 2016, AC Immune SA reported revenue of $20.59MM vs $23.57MM (down 12.66%) and basic earnings per share -$0.47 vs -$0.14. AC Immune SA is expected to report earnings on May 10th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$1.25 and is expected to report on March 19th, 2019.

For the three months ended December 31st, 2017 vs December 31st, 2016, GSV Capital reported revenue of -$0.03MM vs $0.60MM and basic earnings per share -$0.11 vs -$1.42. For the twelve months ended December 31st, 2017 vs December 31st, 2016, GSV Capital reported revenue of $0.85MM vs $0.74MM (up 15.82%) and basic earnings per share $0.80 vs -$3.38. GSV Capital is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.22.

For the three months ended December 31st, 2017 vs December 31st, 2016, Novartis AG reported revenue of $13,164.00MM vs $12,606.00MM (up 4.43%) and basic earnings per share $0.85 vs $0.40 (up 112.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Novartis AG reported revenue of $50,135.00MM vs $49,436.00MM (up 1.41%) and basic earnings per share $3.28 vs $2.82 (up 16.31%). Novartis AG is expected to report earnings on April 19th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.13. The estimated EPS forecast for the next fiscal year is $5.75 and is expected to report on January 23rd, 2019.

For the three months ended October 31st, 2017 vs October 31st, 2016, New York reported revenue of $214.18MM vs $213.90MM (up 0.13%) and basic earnings per share $0.01 vs -$0.04. For the twelve months ended January 31st, 2017 vs January 31st, 2016, New York reported revenue of $929.08MM vs $950.11MM (down 2.21%) and basic earnings per share -$0.27 vs -$0.16. New York is expected to report earnings on May 17th, 2018. The report will be for the fiscal period ending April 30th, 2018.

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.